NEO
NeoGenomics, Inc.
Price Chart
Latest Quote
$11.47
+0.27 (+2.41%)
Current Price
| Previous Close | $11.20 |
| Open | $11.14 |
| Day High | $11.67 |
| Day Low | $11.13 |
| Volume | 3,418,817 |
Stock Information
| Shares Outstanding | 130.21M |
| Total Debt | $408.53M |
| Cash Equivalents | $146.14M |
| Revenue | $745.97M |
| Net Income | $-99.21M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $1.49B |
| EPS (TTM) | $-0.77 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.76B |
| Sales | $745.97M |
| Income | $-99.21M |
| Book/sh | $6.49 |
| Cash/sh | $1.12 |
| Employees | 2K |
Financial Ratios
| Quick Ratio | 3.71 |
| Current Ratio | 4.42 |
| Debt/Eq | 49.29 |
Returns & Margins
| ROA | -2.64% |
| ROE | -11.56% |
| Gross Margin | 43.10% |
| Operating Margin | -9.34% |
| Profit Margin | -13.30% |
Ownership
| Insider Ownership | 2.06% |
| Institutional Ownership | 108.38% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 31.46 |
| PEG | 2.09 |
| P/S | 2.00 |
| P/B | 1.77 |
Analyst Data
| Recommendation | buy |
| Target Price | $15.06 |
Technical Indicators
| SMA20 | $10.73 |
| SMA50 | $9.46 |
| SMA200 | $10.03 |
| RSI | 64.45 |
| ATR | 0.6564 |
| Shares Float | 118.22M |
| Short Float | 7.67% |
| Short Ratio | 4.35 |
| Volatility | 1.81 |
| Rel Volume | 1.29 |
Performance History
| Week | +3.43% |
| Month | +25.91% |
| Quarter | +41.60% |
| 6 Months | -1.80% |
| YTD | -2.47% |
| Year | +63.86% |
| 3 Years | -29.37% |
| 5 Years | -73.69% |
| 10 Years | +43.38% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $11.47 | 3,521,900 |
| 2026-06-22 | $11.20 | 3,108,100 |
| 2026-06-18 | $11.13 | 6,707,600 |
| 2026-06-17 | $10.38 | 13,956,700 |
| 2026-06-16 | $10.49 | 4,968,200 |
| 2026-06-15 | $11.09 | 834,100 |
| 2026-06-12 | $11.15 | 1,481,000 |
| 2026-06-11 | $11.47 | 2,312,900 |
| 2026-06-10 | $11.28 | 2,220,500 |
| 2026-06-09 | $11.44 | 1,979,100 |
| 2026-06-08 | $10.95 | 1,175,600 |
| 2026-06-05 | $10.90 | 1,047,100 |
| 2026-06-04 | $11.31 | 2,498,800 |
| 2026-06-03 | $10.14 | 1,282,000 |
| 2026-06-02 | $10.12 | 1,060,500 |
| 2026-06-01 | $10.44 | 1,205,300 |
| 2026-05-29 | $10.52 | 1,939,900 |
| 2026-05-28 | $10.19 | 1,628,800 |
| 2026-05-27 | $9.57 | 861,600 |
| 2026-05-26 | $9.27 | 850,500 |
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
đ° Latest News
1 Unprofitable Stock for Long-Term Investors and 2 Facing Headwinds
StockStory âĸ 2026-06-19T16:36:58Z
NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-06-19T11:09:00Z
Is NeoGenomics (NEO) Using Its ASCO ctDNA Focus To Redefine Its Precision Oncology Edge?
Simply Wall St. âĸ 2026-05-27T19:03:12Z
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know
StockStory âĸ 2026-05-17T09:24:55Z
3 Russell 2000 Stocks Weâre Skeptical Of
StockStory âĸ 2026-05-12T14:04:55Z
A Look At NeoGenomics (NEO) Valuation After Q1 2026 Results And Epic Aura Oncology Integration
Simply Wall St. âĸ 2026-05-01T07:33:26Z
NeoGenomics Shares Jump on Earnings and Analyst Upgrades
InvestorsHub âĸ 2026-04-29T11:27:26Z
NeoGenomics Inc (NEO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
GuruFocus.com âĸ 2026-04-29T07:09:15ZNeoGenomics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-04-28T22:47:35Z
NeoGenomics (NEO) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-04-28T22:12:50Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $378,908,000 | $331,815,000 | $308,440,000 | $285,173,000 |
| Cost Of Revenue | $413,039,000 | $370,466,000 | $347,039,000 | $321,832,000 |
| Total Revenue | $727,332,000 | $660,566,000 | $591,643,000 | $509,728,000 |
| Operating Revenue | $727,332,000 | $660,566,000 | $591,643,000 | $509,728,000 |
| Expenses | ||||
| Interest Expense | $3,753,000 | $6,617,000 | $6,907,000 | $7,581,000 |
| Total Expenses | $815,460,000 | $746,014,000 | $688,291,000 | $662,835,000 |
| Other Income Expense | $-27,457,000 | $-7,037,000 | $-10,444,000 | $-4,729,000 |
| Other Non Operating Income Expenses | $296,000 | $-379,000 | $644,000 | $-213,000 |
| Net Non Operating Interest Income Expense | $5,317,000 | $11,810,000 | $9,995,000 | $-1,506,000 |
| Interest Expense Non Operating | $3,753,000 | $6,617,000 | $6,907,000 | $7,581,000 |
| Operating Expense | $402,421,000 | $375,548,000 | $341,252,000 | $341,003,000 |
| Selling And Marketing Expense | $91,916,000 | $84,625,000 | $70,842,000 | $67,321,000 |
| General And Administrative Expense | $239,735,000 | $225,868,000 | $209,117,000 | $210,585,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-108,025,000 | $-78,726,000 | $-87,968,000 | $-144,250,000 |
| Net Interest Income | $5,317,000 | $11,810,000 | $9,995,000 | $-1,506,000 |
| Interest Income | $9,070,000 | $18,427,000 | $16,902,000 | $6,075,000 |
| Normalized Income | $-80,835,386 | $-72,229,124 | $-77,922,272 | $-140,161,214 |
| Net Income From Continuing And Discontinued Operation | $-108,025,000 | $-78,726,000 | $-87,968,000 | $-144,250,000 |
| Total Operating Income As Reported | $-115,881,000 | $-92,106,000 | $-107,736,000 | $-157,623,000 |
| Net Income Common Stockholders | $-108,025,000 | $-78,726,000 | $-87,968,000 | $-144,250,000 |
| Net Income | $-108,025,000 | $-78,726,000 | $-87,968,000 | $-144,250,000 |
| Net Income Including Noncontrolling Interests | $-108,025,000 | $-78,726,000 | $-87,968,000 | $-144,250,000 |
| Net Income Continuous Operations | $-108,025,000 | $-78,726,000 | $-87,968,000 | $-144,250,000 |
| Pretax Income | $-110,268,000 | $-80,675,000 | $-97,097,000 | $-159,342,000 |
| Special Income Charges | $-27,753,000 | $-6,658,000 | $-11,088,000 | $-4,516,000 |
| Interest Income Non Operating | $9,070,000 | $18,427,000 | $16,902,000 | $6,075,000 |
| Operating Income | $-88,128,000 | $-85,448,000 | $-96,648,000 | $-153,107,000 |
| Depreciation Amortization Depletion Income Statement | $33,693,000 | $33,896,000 | $33,984,000 | $32,771,000 |
| Depreciation And Amortization In Income Statement | $33,693,000 | $33,896,000 | $33,984,000 | $32,771,000 |
| Amortization Of Intangibles Income Statement | $12,804,000 | $13,808,000 | $15,495,000 | $14,646,000 |
| Depreciation Income Statement | $20,889,000 | $20,088,000 | $18,489,000 | $18,125,000 |
| Gross Profit | $314,293,000 | $290,100,000 | $244,604,000 | $187,896,000 |
| Earnings From Equity Interest | - | - | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $-0.84 | $-0.62 | $-0.70 | $-1.16 |
| Basic EPS | $-0.84 | $-0.62 | $-0.70 | $-1.16 |
| Other | ||||
| Tax Effect Of Unusual Items | $-563,386 | $-161,124 | $-1,042,272 | $-427,214 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-10,938,000 | $5,147,000 | $-6,519,000 | $-77,815,000 |
| Total Unusual Items | $-27,753,000 | $-6,658,000 | $-11,088,000 | $-4,516,000 |
| Total Unusual Items Excluding Goodwill | $-27,753,000 | $-6,658,000 | $-11,088,000 | $-4,516,000 |
| Reconciled Depreciation | $67,824,000 | $72,547,000 | $72,583,000 | $69,430,000 |
| EBITDA (Bullshit earnings) | $-38,691,000 | $-1,511,000 | $-17,607,000 | $-82,331,000 |
| EBIT | $-106,515,000 | $-74,058,000 | $-90,190,000 | $-151,761,000 |
| Diluted Average Shares | $128,101,000 | $126,658,000 | $125,502,000 | $124,217,000 |
| Basic Average Shares | $128,101,000 | $126,658,000 | $125,502,000 | $124,217,000 |
| Diluted NI Availto Com Stockholders | $-108,025,000 | $-78,726,000 | $-87,968,000 | $-144,250,000 |
| Tax Provision | $-2,243,000 | $-1,949,000 | $-9,129,000 | $-15,092,000 |
| Impairment Of Capital Assets | $27,753,000 | $0 | $0 | - |
| Restructuring And Mergern Acquisition | $0 | $6,658,000 | $11,088,000 | $4,516,000 |
| Amortization | $12,804,000 | $13,808,000 | $15,495,000 | $14,646,000 |
| Research And Development | $37,077,000 | $31,159,000 | $27,309,000 | $30,326,000 |
| Selling General And Administration | $331,651,000 | $310,493,000 | $279,959,000 | $277,906,000 |
| Other Gand A | $239,735,000 | $225,868,000 | $209,117,000 | $210,585,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $25,690,000 | $39,892,000 | $45,643,000 | $66,997,000 |
| Total Assets | $1,359,830,000 | $1,638,038,000 | $1,681,229,000 | $1,740,034,000 |
| Total Non Current Assets | $983,544,000 | $1,042,019,000 | $1,084,417,000 | $1,134,743,000 |
| Other Non Current Assets | $9,394,000 | $5,886,000 | $4,742,000 | $5,109,000 |
| Goodwill And Other Intangible Assets | $810,872,000 | $862,447,000 | $895,894,000 | $931,026,000 |
| Other Intangible Assets | $286,528,000 | $339,681,000 | $373,128,000 | $408,260,000 |
| Current Assets | $376,286,000 | $596,019,000 | $596,812,000 | $605,291,000 |
| Other Current Assets | $7,417,000 | $11,722,000 | $8,239,000 | $8,077,000 |
| Prepaid Assets | $21,443,000 | $20,165,000 | $17,987,000 | $15,237,000 |
| Inventory | $28,566,000 | $26,748,000 | $24,156,000 | $24,277,000 |
| Receivables | $159,242,000 | $150,540,000 | $131,227,000 | $119,711,000 |
| Accounts Receivable | $159,242,000 | $150,540,000 | $131,227,000 | $119,711,000 |
| Cash Cash Equivalents And Short Term Investments | $159,618,000 | $386,844,000 | $415,203,000 | $437,989,000 |
| Cash And Cash Equivalents | $159,618,000 | $367,012,000 | $342,488,000 | $263,180,000 |
| Assets Held For Sale Current | - | - | - | $0 |
| Debt | ||||
| Net Debt | $182,240,000 | $174,100,000 | $195,710,000 | $272,142,000 |
| Total Debt | $409,456,000 | $605,334,000 | $611,679,000 | $610,928,000 |
| Long Term Debt And Capital Lease Obligation | $404,680,000 | $401,176,000 | $606,069,000 | $604,274,000 |
| Long Term Debt | $341,858,000 | $340,335,000 | $538,198,000 | $535,322,000 |
| Current Debt And Capital Lease Obligation | $4,776,000 | $204,158,000 | $5,610,000 | $6,654,000 |
| Current Debt | - | $200,777,000 | - | - |
| Other Current Borrowings | - | $200,777,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $523,268,000 | $735,699,000 | $739,692,000 | $742,011,000 |
| Total Non Current Liabilities Net Minority Interest | $434,968,000 | $434,458,000 | $643,388,000 | $652,079,000 |
| Other Non Current Liabilities | $12,069,000 | $11,772,000 | $13,034,000 | $13,055,000 |
| Non Current Deferred Liabilities | $18,219,000 | $21,510,000 | $24,285,000 | $34,750,000 |
| Non Current Deferred Taxes Liabilities | $18,219,000 | $21,510,000 | $24,285,000 | $34,750,000 |
| Current Liabilities | $88,300,000 | $301,241,000 | $96,304,000 | $89,932,000 |
| Current Deferred Liabilities | $851,000 | $409,000 | $2,130,000 | $7,557,000 |
| Payables And Accrued Expenses | $35,093,000 | $34,231,000 | $35,403,000 | $35,580,000 |
| Payables | $23,090,000 | $21,607,000 | $20,334,000 | $20,510,000 |
| Accounts Payable | $23,090,000 | $21,607,000 | $20,334,000 | $20,510,000 |
| Equity | ||||
| Common Stock Equity | $836,562,000 | $902,339,000 | $941,537,000 | $998,023,000 |
| Total Equity Gross Minority Interest | $836,562,000 | $902,339,000 | $941,537,000 | $998,023,000 |
| Stockholders Equity | $836,562,000 | $902,339,000 | $941,537,000 | $998,023,000 |
| Gains Losses Not Affecting Retained Earnings | $4,000 | $-206,000 | $-1,674,000 | $-3,899,000 |
| Other Equity Adjustments | $4,000 | $-206,000 | $-1,674,000 | $-3,899,000 |
| Retained Earnings | $-433,806,000 | $-325,781,000 | $-247,055,000 | $-159,087,000 |
| Long Term Equity Investment | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $128,989,152 | $128,145,333 | $127,369,142 | $126,913,992 |
| Share Issued | $128,989,152 | $128,145,333 | $127,369,142 | $126,913,992 |
| Tangible Book Value | $25,690,000 | $39,892,000 | $45,643,000 | $66,997,000 |
| Invested Capital | $1,178,420,000 | $1,443,451,000 | $1,479,735,000 | $1,533,345,000 |
| Working Capital | $287,986,000 | $294,778,000 | $500,508,000 | $515,359,000 |
| Capital Lease Obligations | $67,598,000 | $64,222,000 | $73,481,000 | $75,606,000 |
| Total Capitalization | $1,178,420,000 | $1,242,674,000 | $1,479,735,000 | $1,533,345,000 |
| Additional Paid In Capital | $1,270,235,000 | $1,228,198,000 | $1,190,139,000 | $1,160,882,000 |
| Capital Stock | $129,000 | $128,000 | $127,000 | $127,000 |
| Common Stock | $129,000 | $128,000 | $127,000 | $127,000 |
| Long Term Capital Lease Obligation | $62,822,000 | $60,841,000 | $67,871,000 | $68,952,000 |
| Current Deferred Revenue | $851,000 | $409,000 | $2,130,000 | $7,557,000 |
| Current Capital Lease Obligation | $4,776,000 | $3,381,000 | $5,610,000 | $6,654,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $47,580,000 | $62,443,000 | $53,161,000 | $40,141,000 |
| Current Accrued Expenses | $12,003,000 | $12,624,000 | $15,069,000 | $15,070,000 |
| Goodwill | $524,344,000 | $522,766,000 | $522,766,000 | $522,766,000 |
| Net PPE | $163,278,000 | $173,686,000 | $183,781,000 | $198,608,000 |
| Accumulated Depreciation | $-209,057,000 | $-189,990,000 | $-158,211,000 | $-131,930,000 |
| Gross PPE | $372,335,000 | $363,676,000 | $341,992,000 | $330,538,000 |
| Leases | $59,406,000 | $57,571,000 | $49,227,000 | $44,418,000 |
| Construction In Progress | $7,727,000 | $8,511,000 | $3,612,000 | $8,984,000 |
| Other Properties | $182,695,000 | $180,919,000 | $190,330,000 | $187,868,000 |
| Machinery Furniture Equipment | $122,507,000 | $116,675,000 | $98,823,000 | $89,268,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $0 | $19,832,000 | $72,715,000 | $174,809,000 |
| Investments And Advances | - | - | - | - |
| Investmentsin Associatesat Cost | - | - | - | - |
| Buildings And Improvements | - | - | - | - |
| Land And Improvements | - | - | - | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-21,778,000 | $-34,038,000 | $-30,705,000 | $-96,884,000 |
| Operating Activities | ||||
| Operating Cash Flow | $5,230,000 | $7,023,000 | $-1,953,000 | $-65,993,000 |
| Cash Flow From Continuing Operating Activities | $5,230,000 | $7,023,000 | $-1,953,000 | $-65,993,000 |
| Operating Gains Losses | $31,000 | $-49,000 | $292,000 | $810,000 |
| Investing Activities | ||||
| Capital Expenditure | $-27,008,000 | $-41,061,000 | $-28,752,000 | $-30,891,000 |
| Investing Cash Flow | $-12,336,000 | $12,855,000 | $76,707,000 | $517,000 |
| Cash Flow From Continuing Investing Activities | $-12,336,000 | $12,855,000 | $76,707,000 | $517,000 |
| Net Other Investing Changes | $1,566,000 | - | - | $12,098,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $962,000 | $4,646,000 | $4,624,000 | $12,587,000 |
| Financing Cash Flow | $-200,288,000 | $4,646,000 | $4,554,000 | $11,829,000 |
| Cash Flow From Continuing Financing Activities | $-200,288,000 | $4,646,000 | $4,554,000 | $11,829,000 |
| Net Common Stock Issuance | $962,000 | $4,646,000 | $4,624,000 | $12,587,000 |
| Common Stock Issuance | $962,000 | $4,646,000 | $4,624,000 | $12,587,000 |
| Net Other Financing Charges | - | - | $-70,000 | $-758,000 |
| Other | ||||
| Repayment Of Debt | $-201,250,000 | $0 | $0 | $0 |
| Interest Paid Supplemental Data | $1,691,000 | $3,829,000 | $3,380,000 | $3,404,000 |
| Income Tax Paid Supplemental Data | $515,000 | $207,000 | $175,000 | $180,000 |
| End Cash Position | $159,618,000 | $367,012,000 | $342,488,000 | $263,180,000 |
| Beginning Cash Position | $367,012,000 | $342,488,000 | $263,180,000 | $316,827,000 |
| Changes In Cash | $-207,394,000 | $24,524,000 | $79,308,000 | $-53,647,000 |
| Net Issuance Payments Of Debt | $-201,250,000 | $0 | $0 | $0 |
| Net Long Term Debt Issuance | $-201,250,000 | $0 | $0 | $0 |
| Long Term Debt Payments | $-201,250,000 | $0 | $0 | $0 |
| Net Investment Purchase And Sale | $19,560,000 | $53,916,000 | $105,459,000 | $19,310,000 |
| Sale Of Investment | $20,060,000 | $53,916,000 | $112,215,000 | $116,915,000 |
| Purchase Of Investment | $-500,000 | $0 | $-6,756,000 | $-97,605,000 |
| Net Business Purchase And Sale | $-6,454,000 | $0 | $0 | $0 |
| Purchase Of Business | $-6,454,000 | $0 | $0 | $0 |
| Net PPE Purchase And Sale | $-27,008,000 | $-41,061,000 | $-28,752,000 | $-30,891,000 |
| Purchase Of PPE | $-27,008,000 | $-41,061,000 | $-28,752,000 | $-30,891,000 |
| Change In Working Capital | $-32,095,000 | $-32,630,000 | $-25,493,000 | $-31,701,000 |
| Change In Other Working Capital | $-3,359,000 | $-3,070,000 | $-11,193,000 | $-16,098,000 |
| Change In Other Current Liabilities | $-2,215,000 | $-5,999,000 | $-7,623,000 | $-8,557,000 |
| Change In Payables And Accrued Expense | $-20,355,000 | $5,282,000 | $8,473,000 | $2,795,000 |
| Change In Accrued Expense | $-15,665,000 | $9,283,000 | $13,020,000 | $1,837,000 |
| Change In Payable | $-4,690,000 | $-4,001,000 | $-4,547,000 | $958,000 |
| Change In Account Payable | $-4,690,000 | $-4,001,000 | $-4,547,000 | $958,000 |
| Change In Prepaid Assets | $1,555,000 | $-6,831,000 | $-3,180,000 | $-1,160,000 |
| Change In Inventory | $-1,543,000 | $-2,699,000 | $-454,000 | $-1,100,000 |
| Change In Receivables | $-6,178,000 | $-19,313,000 | $-11,516,000 | $-7,581,000 |
| Changes In Account Receivables | $-6,178,000 | $-19,313,000 | $-11,516,000 | $-7,581,000 |
| Other Non Cash Items | $8,426,000 | $12,018,000 | $12,297,000 | $14,328,000 |
| Stock Based Compensation | $41,316,000 | $33,413,000 | $24,633,000 | $24,672,000 |
| Asset Impairment Charge | $27,753,000 | $450,000 | $1,703,000 | $718,000 |
| Depreciation Amortization Depletion | $67,824,000 | $72,547,000 | $72,583,000 | $69,430,000 |
| Depreciation And Amortization | $67,824,000 | $72,547,000 | $72,583,000 | $69,430,000 |
| Amortization Cash Flow | $31,752,000 | $33,446,000 | $35,133,000 | $34,058,000 |
| Amortization Of Intangibles | $31,752,000 | $33,446,000 | $35,133,000 | $34,058,000 |
| Depreciation | $36,072,000 | $39,101,000 | $37,450,000 | $35,372,000 |
| Net Income From Continuing Operations | $-108,025,000 | $-78,726,000 | $-87,968,000 | $-144,250,000 |
| Issuance Of Debt | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Earnings Losses From Equity Investments | - | - | $0 | $0 |
| Change In Other Current Assets | - | - | - | $-8,557,000 |
Fetched: 2026-06-23